Abstract
As the number of new and recovering cases continues to rise, it is increasingly important to understand the long-term impacts of COVID-19 beyond the time of active SARS-CoV-2 infection. We previously used augmented curation methods to analyze physician notes from a large EHR system and identified anemia and acute kidney injury as risk factors for admission to the hospital after PCR confirmation of viral clearance in COVID-19 patients. Here, we analyzed longitudinal lab testing data from this same patient cohort to determine whether these measurements corroborate our notes-derived findings. Indeed we found that COVID-19 patients hospitalized after confirmed viral clearance tended to have lower hemoglobin and hematocrit measurements both during their SARS-CoV-2 positive intervals and during the one year prior to COVID-19 diagnosis compared to patients who have not been rehospitalized after viral clearance. Further, outright laboratory-based diagnosis of moderate or severe anemia was strongly enriched in the hospitalized cohort, suggesting that anemia pre-dating or concurrent with SARS-CoV-2 infection may predispose patients to long-term complications of COVID-19. Interventions which may mitigate anemia did not reduce the risk of post clearance hospitalization, although the efficacy of and patient compliance with these interventions could not be established. This study demonstrates the value of integrated large-scale EHR analyses and highlights the need for further research to determine whether the prevention or mitigation of anemia during SARS-CoV-2 infection may reduce the risk of suffering long-term complications of COVID-19.
Competing Interest Statement
ADB is a consultant for Abbvie, is on scientific advisory boards for Nference and Zentalis, and is founder and President of Splissen therapeutics. One or more of the investigators associated with this project and Mayo Clinic have a Financial Conflict of Interest in technology used in the research and that the investigator(s) and Mayo Clinic may stand to gain financially from the successful outcome of the research. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies. The authors from nference have financial interests in the company.
Funding Statement
ADB is supported by Grants AI 110173 and AI120698 from NIAID, 109593-62-RGRL from Amfar, and the HH Sheikh Khalifa Bin Zayed Al-Nahyan named professorship from Mayo Clinic.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This retrospective research was conducted with approval from the Mayo Clinic Institutional Review Board (IRB 20003278)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Reasonable requests for the de-identified data may be made to corresponding author upon publication of the peer-reviewed manuscripts.
